Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR.

Trial Profile

Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Octreotide (Primary)
  • Indications Carcinoid tumour; Diarrhoea; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top